Xiao Liehui, Secretary of Shenzhen Hospital of Southern Medical University, and his delegation visited Shenzhen Cell Valley
Under the leadership of Professor Shi Yuanyuan, Secretary Xiao and his delegation visited the Smart Exhibition Hall and digital monitoring system, and gained a preliminary understanding of the development history, core team, production, research and development, quality management, and industrialization talent training base of Shenzhen Cell Valley.
At the symposium, Professor Shi Yuanyuan provided a detailed introduction to the current status of cell therapy both domestically and internationally, as well as our company's strategic layout and core technologies. Professor Shi Yuanyuan stated that the Shenzhen Cell Valley South China Cell Factory project is a major municipal project approved by the Shenzhen Development and Reform Commission, and also a major public service platform for the Shenzhen biopharmaceutical industry. It collaborates with numerous tertiary hospitals to promote clinical research and application development of cell therapy. Cell therapy has achieved significant success in improving patient survival rates and reducing the burden of cancer. Our company utilizes domestically leading GMP level industrial production technology for retroviral vectors and has provided high-quality and safe customized CAR cell preparation services for multiple well-known medical institutions both domestically and internationally. Dozens of blood tumor patients who had previously failed treatment and experienced recurrence or drug resistance showed significant relief after CAR-T cell therapy prepared by the Cell Valley team. At the same time, NK and CAR-NK cell therapy products recently launched by Cell Valley have been widely used in the clinical research of solid tumors and autoimmune diseases such as liver cancer and pancreatic cancer. Shenzhen Cell Valley always adheres to the mission values of "cells benefit sentient beings, genes create the future", and is committed to solving key constraints such as technology, cost, production capacity, and talent in cell therapy drugs/clinical treatments, and opening up more treatment pathways for patients.
Secretary Xiao Liehui of Shenzhen Hospital of Southern Medical University stated that cell therapy is becoming a new focus in the development of the medical and health industry. The future clinical cell therapy model will be full cycle and all-round, and its popularization and promotion cannot be separated from the unremitting technological development of scientific research teams and the application transformation of high-level clinical diagnosis and treatment teams. The Clinical Medicine Innovation Center of Southern Medical University Shenzhen Hospital is a comprehensive platform integrating basic medicine, clinical translation, and precision medicine, approved by the Shenzhen Development and Reform Commission. It can conduct scientific research around clinical problems and explore more innovative and effective treatment methods for patients.
Both parties have stated that they will fully leverage their respective technological resources, core teams, and platform advantages to jointly contribute to the clinical application of cell therapy.
